Cargando…
Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022
ABSTRACT: Interest in possible clinical uses for psychedelic drugs has grown steadily over the past decade. Although impressive findings from small studies stimulated considerable speculation and provided a strong justification for further study of psychedelic treatments, until very recently there w...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417937/ http://dx.doi.org/10.1192/j.eurpsy.2023.42 |
_version_ | 1785088158276255744 |
---|---|
author | Bogenschutz, M. |
author_facet | Bogenschutz, M. |
author_sort | Bogenschutz, M. |
collection | PubMed |
description | ABSTRACT: Interest in possible clinical uses for psychedelic drugs has grown steadily over the past decade. Although impressive findings from small studies stimulated considerable speculation and provided a strong justification for further study of psychedelic treatments, until very recently there was a dearth of high-quality evidence for their efficacy, mechanisms of action, and appropriate treatment models for clinical use. However, during the past 2-3 years, there have been dramatic advances in the field. This presentation will focus on 5 publications in the field of psychedelic medicine that exemplify three important aspects of the recent progress in psychedelic research. (1) There has been a rapid increase in the number and size of controlled clinical trials of various psychedelic treatments. (2) Conceptual models for studying and potentially understanding the therapeutic effect of psychedelics have increased in sophistication and comprehensiveness. And (3) progress has been made toward developing models of treatment that would facilitate access to safe and effective psychedelic treatments, if and when they are approved by regulatory bodies. Although progress has been rapid, the field of psychedelic medicine is still in its infancy. Much more work on these and many other fronts will be necessary to discover what the study of psychedelics can contribute to healthcare and neuroscience. DISCLOSURE OF INTEREST: None Declared |
format | Online Article Text |
id | pubmed-10417937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-104179372023-08-12 Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022 Bogenschutz, M. Eur Psychiatry Abstract ABSTRACT: Interest in possible clinical uses for psychedelic drugs has grown steadily over the past decade. Although impressive findings from small studies stimulated considerable speculation and provided a strong justification for further study of psychedelic treatments, until very recently there was a dearth of high-quality evidence for their efficacy, mechanisms of action, and appropriate treatment models for clinical use. However, during the past 2-3 years, there have been dramatic advances in the field. This presentation will focus on 5 publications in the field of psychedelic medicine that exemplify three important aspects of the recent progress in psychedelic research. (1) There has been a rapid increase in the number and size of controlled clinical trials of various psychedelic treatments. (2) Conceptual models for studying and potentially understanding the therapeutic effect of psychedelics have increased in sophistication and comprehensiveness. And (3) progress has been made toward developing models of treatment that would facilitate access to safe and effective psychedelic treatments, if and when they are approved by regulatory bodies. Although progress has been rapid, the field of psychedelic medicine is still in its infancy. Much more work on these and many other fronts will be necessary to discover what the study of psychedelics can contribute to healthcare and neuroscience. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10417937/ http://dx.doi.org/10.1192/j.eurpsy.2023.42 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Bogenschutz, M. Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022 |
title | Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022 |
title_full | Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022 |
title_fullStr | Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022 |
title_full_unstemmed | Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022 |
title_short | Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022 |
title_sort | evidence that moved psychedelic medicine from the fringe to the mainstream in 2022 |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417937/ http://dx.doi.org/10.1192/j.eurpsy.2023.42 |
work_keys_str_mv | AT bogenschutzm evidencethatmovedpsychedelicmedicinefromthefringetothemainstreamin2022 |